Esperion Therapeutics Files 8-K Amendment
Ticker: ESPR · Form: 8-K/A · Filed: Aug 11, 2025 · CIK: 1434868
| Field | Detail |
|---|---|
| Company | Esperion Therapeutics, Inc. (ESPR) |
| Form Type | 8-K/A |
| Filed Date | Aug 11, 2025 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, sec-filing, regulatory
Related Tickers: ESPR
TL;DR
Esperion filed an amendment to its 8-K, likely fixing or adding details to a prior report.
AI Summary
Esperion Therapeutics, Inc. filed an amendment (8-K/A) on August 11, 2025, to its current report originally filed on August 5, 2025. This amendment pertains to Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits) of the Form 8-K. The filing does not provide new financial results or operational updates but rather amends previous disclosures.
Why It Matters
This filing indicates a correction or addition to a previous report, suggesting a need for updated or clarified information regarding Esperion's operations or financial condition.
Risk Assessment
Risk Level: low — This is an amendment to a previous filing, not a new event, and does not appear to contain significant new financial or operational information.
Key Numbers
- 001-35986 — SEC File Number (Identifies the specific SEC filing for Esperion Therapeutics, Inc.)
Key Players & Entities
- Esperion Therapeutics, Inc. (company) — Registrant
- August 5, 2025 (date) — Date of earliest event reported
- August 11, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- Ann Arbor, MI (location) — Principal executive offices
FAQ
What specific items are being amended in this 8-K/A filing?
This 8-K/A amends Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits) of the original Form 8-K.
What was the original filing date that this amendment refers to?
The original filing date that this amendment refers to is August 5, 2025.
What is the exact date this amendment was filed with the SEC?
This amendment was filed with the SEC on August 11, 2025.
What is the principal business address of Esperion Therapeutics, Inc.?
The principal business address is 3891 Ranchero Drive, Suite 150, Ann Arbor, MI 48108.
What is the SIC code for Esperion Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Esperion Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,202 words · 5 min read · ~4 pages · Grade level 11.9 · Accepted 2025-08-11 08:02:26
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share ESPR NASDAQ Stock Market LLC
Filing Documents
- espr-20250805.htm (8-K/A) — 31KB
- a991q22025earningsreleasea.htm (EX-99.1) — 95KB
- 0001628280-25-039392.txt ( ) — 264KB
- espr-20250805.xsd (EX-101.SCH) — 2KB
- espr-20250805_lab.xml (EX-101.LAB) — 23KB
- espr-20250805_pre.xml (EX-101.PRE) — 13KB
- espr-20250805_htm.xml (XML) — 4KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On August 11, 2025, the Company furnished a press release announcing certain of its preliminary financial results for the three and six months ended June 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1. The Company has not yet completed its quarter-end financial close process for the quarter ended June 30, 2025. The preliminary financial data included in Exhibit 99.1 attached hereto has been prepared by, and is the responsibility of, the Company's management, is based on preliminary unaudited information and management estimates for the quarter ended June 30, 2025, is not a comprehensive statement of the Company's financial results, and is subject to completion of the Company's financial closing procedures. There can be no assurance that the Company's actual financial results as of June 30, 2025 will not differ from these estimates, including as a result of the completion of the Company's final adjustments, and other developments that may arise between the date of this filing and the time the Company's financial results for such period are finalized, and any such changes could be material. These estimates should not be viewed as a substitute for interim financial statements prepared in accordance with accounting principles generally accepted in the United States and they are not necessarily indicative of the results to be achieved in any future period. Complete results as of June 30, 2025 will be included in the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025. The Company assumes no duty to update these preliminary estimates, except as required by law. The information set forth under Item 2.02 and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor sh
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated August 11 , 2025 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 11, 2025 Esperion Therapeutics, Inc. By: /s/ Sheldon L. Koenig Sheldon L. Koenig President and Chief Executive Officer